Vice President/Sr. Director, Head of GU Oncology Lifecycle Management at Natera

San Carlos, California, United States

Apply Now

Not SpecifiedCompensation

Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Oncology, HealthcareIndustries

Requirements

Bachelor’s degree, Advanced degree preferred (MBA or PhD)
GU oncology market experience strongly preferred
8-10 years experience in product marketing, market analytics at a pharmaceutical / biotech company
Previous KOL management experience preferred
Working knowledge of oncology molecular testing / biomarkers
~25% travel required (advisory boards, congresses, sales / marketing meetings, customer meetings)
Ability to lead without authority, influence and inspire individuals
Proven strategic agility with an enterprise mindset and ability to operate with executive presence
Ability to partner and collaborate across a broad range of internal and external partners
Strong customer orientation and focus, particularly establishing thought leader relationships
Proven ability to communicate the complex simply (biomarkers, multiple indications, etc.)
Strong organizational / time management skills; manage and complete multiple projects

Responsibilities

Own the lifecycle planning and success of GU cancers, collaborating with cross-functional teams to develop and execute a strategic plan that drives usage, awareness, and advocacy across key stakeholders worldwide
Expand Signatera access across GU tumors – prioritize key indications, own evidence roadmaps, close evidence gaps and submit for coverage
Establish tumor-specific goals to be owned by the lifecycle team and across functions
Serve as a critical member on clinical / medical teams, helping define and prioritize key indications while identifying and addressing evidence gaps
Monitor performance & mitigate risks – In close partnership with Marketing team, track performance and deliver against GU commercial and medical goals, identifying potential issues / risks and implement mitigation strategies
Serve as a critical member on commercial subteams, helping to maximize Natera potential by escalating and addressing critical barriers that limit commercial adoption
Maintain a deep expertise in the GU cancers space by integrating real-time customer insights, publications, data presentations, competitive and market intelligence
Shape the value proposition for Natera’s oncology products in collaboration with Medical Affairs and Commercial Marketing, leveraging clinical evidence and market dynamics
Regularly present strategic plans and progress to executive leadership

Skills

Oncology

Lifecycle Management

Strategic Planning

Cross-Functional Collaboration

Evidence Generation

Commercial Strategy

Medical Affairs

Stakeholder Engagement

Performance Monitoring

Risk Mitigation

GU Cancers

MRD Testing

Natera

Genetic testing and diagnostics solutions provider

About Natera

Natera focuses on genetic testing and diagnostics, providing advanced solutions for cancer patients, transplant patients, and individuals assessing hereditary health risks. Their main technology is cell-free DNA (cfDNA) testing, which analyzes DNA fragments in the blood to detect minimal traces of cancer and assess organ health. Natera stands out by offering specialized tests like the Signatera ctDNA test and Panorama NIPT, along with genetic counseling services. The company's goal is to improve patient care and health outcomes through accurate genetic testing.

Austin, TexasHeadquarters

2004Year Founded

$149.9MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

1,001-5,000Employees

Benefits

Flexible medical plans

Investment options

Time off

Workplace perks

Risks

Hindenburg report accuses Natera of deceptive sales practices, risking legal challenges.

New Prospera Heart features may face slow adoption by healthcare providers.

Fetal RhD NIPT demand may drop post-RhIg shortage, affecting future sales.

Differentiation

Natera's Signatera test offers personalized ctDNA analysis for cancer patients.

Prospera Heart test uses unique Donor Quantity Score for transplant rejection detection.

Panorama NIPT test is a leader in non-invasive prenatal testing with 2 million tests.

Upsides

Increased adoption of liquid biopsy techniques boosts demand for Natera's cfDNA tests.

AI integration enhances accuracy and speed of Natera's cfDNA analysis.

Growing personalized medicine trend aligns with Natera's customized genetic tests.

Land your dream remote job 3x faster with AI

Try Jobo Free